Finding an encouraging drug lead that selectively engages a target of interest is the result of several critical matches that lead to successful drug discovery programmes, including: Matching a small molecule library with an innovative assay technology Matching a primary screening platform with orthogonal assays to validate hits Matching a… Read More
Pairing the right small molecule library with innovative high-throughput screening creates more therapeutic opportunity, this SAMDI Tech case study shows. Finding an encouraging drug lead that selectively engages a target of interest is the result of several matches that lead to successful drug discovery programmes, including: … Read More
Researchers from the University of Dundee and Promega Corporation have shown how a “three-headed hydra” significantly improves efficacy in targeted protein degradation. The research is published in Nature Chemical Biology. Targeted protein degradation is an area of chemical biology that is said to be revolutionising drug discovery. It involves… Read More
RareCan has received approval from the NHS Research Ethics Committee to establish its BioResource at Newcastle University, which will store tissue samples from rare cancer patients collected during surgery, will be accessible to scientists around the globe undertaking research into the prevention, diagnosis or treatment of rare cancers. This reduces… Read More
Elicera Therapeutics, a Swedish clinical stage cell and gene therapy company that develops immuno-oncological treatments focusing on CAR T-cells and oncolytic viruses, has presented preclinical proof-of-concept data for the company’s iTANK-platform at the ESGCT (European Society of Gene & Cell Therapy) Virtual Congress 2021. iTANK (immunoTherapies Activated with NAP for efficient… Read More
Dr Rob Burgess, Chief Business Officer for Sino Biological, has been interviewed on Worldwide Business with Kathy Ireland. This television series examines companies around the world currently impacting different sectors of business and society. “I’m delighted with the chance to outline the company’s global impact on human… Read More
The latest free-to-listen DDW podcast episode is titled “The important role that antibodies play in drug discovery”. It covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine, narrated by DDW’s Megan Thomas. These articles are titled: “Antibody therapeutics: the… Read More
This free-to-listen DDW podcast episode is titled “The important role that antibodies play in drug discovery”. It covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine, narrated by DDW’s Megan Thomas. These articles are titled: “Antibody therapeutics: the… Read More
Ferrer and Treeway have entered into a licence agreement for the development and commercialisation of an oral formulation of edaravone (TW001/FNP122) for Amyotrophic Lateral Sclerosis (ALS) in certain territories, including Europe and some Asian countries. Ferrer is responsible for advancing the development and commercialisation of the product and will make royalty payments to Treeway at certain milestones. The deal… Read More
Culture Biosciences has selected Scispot.io to digitise and automate its media preparation workflows while maintaining an audit trail. Connecting data from multiple sources with Scispot, Culture Bioscience aims to reduce its experiment failure rate and improve the scientific output. “Scispot is designed for mapping custom biomanufacturing workflows developed by Culture Biosciences. Using Scispot, Culture… Read More
Leucid Biohas raised £11.5 million in a Series A financing round, which will be used to initiate a Phase I trial of its lead candidate, LEU-011, for the treatment of platinum resistant ovarian cancer. CAR T-cell therapy is a technology in which the patient’s own immune cells are reprogrammed… Read More
University of Queensland researchers have identified a pathway helping the breast cancer protein BRCA1 repair damaged DNA in a study that will inform future targeted therapies. Professor Robert Parton, Professor Alpha Yap and Dr Kerrie-Ann McMahon from the university’s Institute for Molecular Bioscience (IMB) identified an association between two… Read More
News round-up by DDW’s Megan Thomas for 18-22 October DDW’s Megan Thomas has selected five stories which highlight the opportunities in the drug discovery sector. 1. Researchers receive $4 million for exceptional junior scientists Two Mount Sinai cancer researchers will receive $4… Read More
Many small molecule inhibitors have been approved as cancer therapeutics, but they can confer mutation-based drug resistance and many potential cancer targets remain “undruggable”. One emerging cancer therapeutic strategy that shows promise for drug development is the use of targeted protein degradation (TPD). This approach has many advantages, including the… Read More
Apeiron Biologics has begun a Phase I trial for inhalation of APN01, a recombinant human angiotensin-converting enzyme 2 developed to treat Covid-19 patients by neutralising SARS-CoV-2 in the lungs and mitigating lung damage caused by the infection. The double-blind, placebo-controlled, dose-escalation study plans to enroll about 40 healthy volunteers in Austria… Read More
This paid-for advertorial by Arctoris appeared in the DDW / ELRIG UK Drug Discovery 2021 supplement in DDW Volume 22, Issue 4 – Fall 2021 Oxford-headquartered Arctoris progresses programmes from target to hit, lead, and candidate with superior efficiency, accuracy, and confidence. Key to the company’s capabilities is the unique combination of robotics and… Read More
